Aldose reductase enzyme and its implication to major health problems of the 21st century

Current Medicinal Chemistry

Volumn 16, Issue 6, 2009, Pages 734-752

  Alexiou, Polyxeni ^a   Pegklidou, Kyriaki ^a   Chatzopoulou, Maria ^a   Nicolaou, Iaonnis ^a   Demopoulos, Vassilis J ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Aldose reductase enzyme and aldose reductase inhibitors; Cancer; Cardiovascular disorders; Inflammation; Long term diabetic complications; Mood disorders; Ovarian abnormalities; Renal insufficiency

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 ARYLIDENE 2,4 THIAZOLIDINEDIONE DERIVATIVE; 6 [[(DIPHENYLMETHYLENE)AMINO]OXY]HEXANOIC ACID DERIVATIVE; ACETIC ACID DERIVATIVE; ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; BENZIMIDAZOLE DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; CARBOXYMETHYLATED PYRIDOINDOLE DERIVATIVE; FIBRINOLYTIC AGENT; FIDARESTAT; HYDANTOIN DERIVATIVE; MINALRESTAT; N (3,5 DIFLUOROPHENOL 4 HYDROXYPHENYL)DERIVATIVE; N NITROMETHYLSULFONANILIDE DERIVATIVE; PHENYLACETIC ACID DERIVATIVE; PYRROL 1 YLACETIC ACID DERIVATIVE; RANIRESTAT; SORBINIL; SPIROIMIDE DERIVATIVE; SULFONYLPYRIDAZINONE DERIVATIVE; TETRAHYDROPYRROLO[1,2 A]PYRAZINE 1,3 DIONE DERIVATIVE; THIENOCINNOLINONE CARBOXYLIC ACID DERIVATIVE; TOLRESTAT; UNCLASSIFIED DRUG; ZOPOLRESTAT;

CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CATALYSIS; CELL DAMAGE; CELL STRESS; CRYSTAL STRUCTURE; DETOXIFICATION; DIABETIC KETOACIDOSIS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DNA SYNTHESIS; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; ENZYME ACTIVE SITE; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME SPECIFICITY; ENZYME STABILITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPEROSMOLARITY; INFLAMMATION; KIDNEY FAILURE; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; MICROANGIOPATHY; MOOD DISORDER; MORBIDITY; MORTALITY; NONHUMAN; OSMOREGULATION; OVARY DISEASE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN SYNTHESIS; RACEMIC MIXTURE; REGULATORY MECHANISM; REPERFUSION INJURY; REVIEW; SPERMATOZOON MATURATION; SPERMATOZOON MOTILITY; STRUCTURE ACTIVITY RELATION; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR DISEASE;

ALDEHYDE REDUCTASE; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HUMANS; INFLAMMATION; MOOD DISORDERS; NEOPLASMS; OVARIAN DISEASES; RENAL INSUFFICIENCY;

EID: 65649103414     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709787458362     Document Type: Review

References (171)

1. Demopoulos, V.J.; Zaher, N.; Zika, Ch.; Anagnostou, K., Mamadou, E.; Alexiou, P.; Nicolaou, I. Compounds that combine aldose reductase inhibitory activity and ability to prevent the glycation (glucation and/ or fructation) of proteins as putative pharmacotherapeutic agents. Drug Design Rev. Online 2005, 2, 293-304.
2. Hwang, Y. C.; Sato, S.; Tsai, J.-Y.; Yan, S.; Bakr, S.; Zhang, H.; Oates, P. J.; Ramasamy, R. Aldose reductase activation is a key component of myocardial response to ischemia. FASEB J., 2002, 16, 243-245.
3. Yang, R. B.; Mark, M. R.; Gray, A.; Huang, A.; Xie, M. H.; Zhang, M.; Goddard, A.; Wood, W. I.; Gurney, A. L.; Godowski, P. J. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature, 1998, 395, 284-288.
4. Miller, S. I.; Ernst, R. K.; Bader, M. W. LPS, TLR4 and infectious disease diversity. Nat. Rev. Microb., 2005, 3, 36-46.
5. Regenold, W. T.; Kling, M. A.; Hauser, P. Elevated sorbitol concentration in the cerebrospinal fluid of patients with mood disorders. Psychoneuroendocrinology, 2000, 25, 593-606.
6. Hasuike, Y.; Nakanishi, T.; Otaki, Y.; Nanami, M.; Tanimoto, T.; Taniguchi, N.; Takamitsu, Y. Plasma 3-deoxyglucosone elevation in chronic renal failure is associated with increased aldose reductase in erythrocytes. Am. J. Kidney Dis., 2002, 40, 464-471.
7. Meyer, W. R.; Doyle, M. B.; Grifo, J. A.; Lipetz, K. J.; Oates, P. J.; DeCherney, A. H.; Diamond, M. P. Aldose reductase inhibition prevents galactose-induced ovarian dysfunction in the Sprague-Dawley rat. Am. J. Obstet. Gynecol., 1992, 167, 1837-43.
8. Lee, K. W.; Ko, B. C.; Jiang, Z.; Cao, D.; Chung, S. S. Overexpression of aldose reductase in liver cancers may contribute to drug resistance. Anticancer Drugs, 2001, 12, 129-132.
9. Saraswat, M.; Mrudula, T.; Kumar, P. U.; Suneetha, A.; Rao Rao, T. S.; Srinivasulu, M.; Reddy, B. Overexpression of aldose reductase in human cancer tissues. Med. Sci. Monit., 2006, 12, CR525-529.
10. Jez, J. M.; Bennett, M. J.; Schlegel, B. P.; Lewis, M.; Penning, T. M. Comparative anatomy of the aldo-keto reductase superfamily. Biochem. J., 1997, 326, 625-636.
11. Carper, D. A.; Wistow, G.; Nishimura, C.; Graham, C.; Watanabe, K.; Fujii, Y.; Hayashi, H.; Hayaishi, O. A superfamily of NADPH-dependent reductases in eukaryotes and prokaryotes. Exp. Eye Res., 1989, 49, 377-388.
12. Wilson D. K.; Bohren, K. M.; Gabbay, K. H.; Quiocho, F. A. An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications. Science, 1992, 257, 81-84.
13. Rondeau J. M.; Tete-Favier, F.; Podjarny, A.; Reymann, J. M.; Barth, P.; Biellmann, J. F.; Moras, D. Novel NADPH-binding domain revealed by the crystal structure of aldose reductase. Nature, 1992, 355, 469-472.
14. Wilson D. K.; Tarle, I.; Petrash, J. M.; Quiocho, F. A. Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat. Proc. Natl. Acad. Sci. U. S. A., 1993, 90, 9847-9851.
15. Bohren K. M.; Grimshaw, C. E.; Lai, C. J.; Harrison, D. H.; Ringe, D.; Petsko, G. A.; Gabbay, K. H. Tyrosine-48 is the proton donor and histidine-110 directs substrate stereochemical selectivity in the reduction reaction of human aldose reductase: Enzyme kinetics and crystal structure of the Y48H mutant enzyme. Biochemistry, 1994, 33, 2021-2032.
16. Urzhumtsev, A.; Tete-Favier, F.; Mitschler, A.; Barbanton, J.; Barth, P.; Urzhumtseva, L.; Biellmann, J. F.; Podjarny, A.; Moras, D. A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil. Structure, 1997, 5, 601-612.
17. Lee Y. S.; Chen, Z.; Kador, P. F. Molecular modeling studies of the binding modes of aldose reductase inhibitors at the active site of human aldose reductase. Bioorg. Med. Chem., 1998, 6, 1811-1819.
18. Constantino, L.; Rastelli, G.; Gamberini, M. C.; Vinson, J. A.; Bose, P.; Iannone, A.; Staffieri, M.; Antolini, L.; Del Corso, A.; Mura, U.; Albasini, A. 1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. J. Med. Chem., 1999, 42, 1881-1893.
19. Varnai, P.; Warshel, A. Computer simulation studies of the catalytic mechanism of human aldose reductase. J. Am. Chem. Soc., 2000, 122, 3849-3860.
20. Podjarnya, A.; Cachau, R. E.; Schneider, T.; Van Zandt, M.; Joachimiak, A. Subatomic and atomic crystallographic studies of aldose reductase: implications for inhibitor binding. Cell Mol. Life Sci., 2004, 61, 763-773.
21. Steuber, H.; Zentgraf, M.; Podjarny, A.; Heine, A.; Klebe, G. Highresolution crystal structure of aldose reductase complexed with the novel sulfonyl-pyridazinone inhibitor exhibiting an alternative active site anchoring group. J. Mol. Biol., 2006, 356, 45-56.
22. Steuber, H.; Czodrowski, P.; Sotriffer, C. A.; Klebe, G. Tracing changes in protonation: A prerequisite to factorize thermodynamic data of inhibitor binding to aldose reductase. J. Mol. Biol., 2007, 373, 1305-1320.
23. Bohren K. M.; Grimshaw, C. E. The sorbinil trap: A predicted deadend complex confirms the mechanism of aldose reductase inhibition. Biochemistry, 2000, 39, 9967-9974.
24. Nakano T.; Petrash, J. M. Kinetic and spectroscopic evidence for active site inhibition of human aldose reductase. Biochemistry, 1996, 35, 11196-11202.
25. Sotriffer, C. A.; Kramer, O.; Klebe, G. Probing flexibility and "induced-fit" phenomena in aldose reductase by comparative crystal structure analysis and molecular dynamics simulations. Proteins, 2004, 56, 52-66.
26. Zentgraf, M.; Steuber, H.; Koch, C.; La Motta, C.; Sartini, S.; Sotriffer, C. A.; Klebe, G. How reliable are current docking approaches for structure-based drug design? Lessons from aldose reductase. Angew. Chem. Int. Ed. Engl., 2007, 46, 3575-3578.
27. Dixit, B. L.; Balendiran, G. K.; Watowich, S. J.; Srivastava, S.; Ramana, K. V.; Petrash, J. M.; Bhatnagar, A.; Srivastava, S. K. Kinetic and structural characterization of the glutathione-binding site of aldose reductase. J. Biol. Chem., 2000, 275, 21587-21595.
28. Singh, R.; White, M. A.; Ramana, K. V.; Petrash, J. M.; Watowich, S. J.; Bhatnagar, A.; Srivastava, S. K. Structure of a glutathione conjugate bound to the active site of aldose reductase. Proteins, 2006, 64, 101-110.
29. El-Kabbani, O.; Carbone, V.; Darmanin, C.; Oka, M.; Mitschler, A.; Podjarny, A.; Schulze-Briese, C.; Chung, R. P. Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: Implications for inhibitor binding and selectivity. J. Med. Chem., 2005, 48, 5536-5542.
30. Carper, D. A.; Wistow, G.; Nishimura, C.; Graham, C.; Watanabe, K.; Fujii, Y.; Hayashi, H.; Hayaishi, O. A superfamily of NADPHdependent reductases in eukaryotes and prokaryotes. Exp. Eye Res., 1989, 49, 377-388.
31. El-Kabbani, O.; Wilson, D. K.; Petrash, M.; Quiocho, F. A. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites. Mol. Vis., 1998, 4, 19-26.
32. Bohren, K. M.; Grimshaw, C. E.; Gabbay, K. H. Catalytic effectiveness of human aldose reductase. Critical role of C-terminal domain. J. Biol. Chem., 1992, 267, 20965-20970.
33. Barski, O. A.; Gabbay, K. H.; Bohren, K. M. The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity. Biochemistry, 1996, 35, 14276-14280.
34. Foppiano, M.; Lombardo, G. Worldwide pharmacovigilance systems and tolrestat withdrawal. Lancet, 1997, 349, 399-400.
35. Barski, O. A.; Gabbay, K. H.; Grimshaw, C. E.; Bohren, K. M. Mechanism of human aldehyde reductase: Characterization of the active site pocket. Biochemistry, 1995, 34, 11264-11275.
36. Petrova, T.; Steuber, H.; Hazemann, I.; Cousido-Siah, A.; Mitschler, A.; Chung, R.; Oka, M.; Klebe, G.; El-Kabbani, O.; Joachimiak, A.; Podjarny, A. Factorizing selectivity determinants of inhibitor binding toward aldose and aldehyde reductases: Structural and thermodynamic properties of the aldose reductase mutant Leu300Pro-fidarestat complex. J. Med. Chem., 2005, 48, 5659-5665.
37. Kawamura, M.; Eisenhofer, G.; Kopin, I. J.; Kador, P. F.; Lee, Y. S.; Fujisawa, S.; Sato, S. Aldose reductase: An aldehyde scavenging enzyme in the intraneuronal metabolism of norepinephrine in human sympathetic ganglia. Auton. Neurosci., 2002, 96, 131-139.
38. Wermuth, B.; Monder, C. Aldose and aldehyde reductase exhibit isocorticosteroid reductase activity. Eur. J. Biochem., 1983, 131, 423-426.
39. Matsuura, K.; Deyashiki, Y.; Bunai, Y.; Ohya, I.; Hara, A. Aldose reductase is a major reductase for isocaproaldehyde, a product of side-chain cleavage of cholesterol, in human and animal adrenal glands. Arch. Biochem. Biophys., 1996, 328, 265-271.
40. Srivastava, S.; Chandra, A.; Wang, L. F.; Seifert, W. E., Jr.; Da-Gue, B. B.; Ansari, N. H.; Srivastava, S. K.; Bhatnagar, A. Metabolism of the lipid peroxidation product, 4-hydroxy-trans-2-nonenal, in isolated perfused rat heart. J. Biol. Chem., 1998, 273, 10893-10900.
41. Srivastava, S.; Dixit, B. L.; Cai, J.; Sharma, S.; Hurst, H. E.; Bhatnagar, A.; Srivastava, S. K. Metabolism of lipid peroxidation product, 4-hydroxynonenal (HNE) in rat erythrocytes: Role of aldose reductase. Free Radic. Biol. Med., 2000, 29, 642-651.
42. Srivastava, S.; Spite, M.; Trent, J. O.; West, M. B.; Ahmed, Y.; Bhatnagar, A. Aldose reductase-catalyzed reduction of aldehyde phospholipids. J. Biol. Chem., 2004, 279, 53395-53406.
43. Srivastava, S.; Watowich, S. J.; Petrash, J. M.; Srivastava, S. K.; Bhatnagar, A. Structural and kinetic determinants of aldehyde reduction by aldose reductase. Biochemistry, 1999, 38, 42-54.
44. Vander Jagt, D. L.; Kolb, N. S.; Vander Jagt, T. J.; Chino, J.; Martinez, F. J.; Hunsaker, L. A.; Royer, R. E. Substrate specificity of human aldose reductase: Identification of 4-hydroxynonenal as an endogenous substrate. Biochim. Biophys. Acta, 1995, 1249, 117-126.
45. Srivastava, S.; Chandra, A.; Bhatnagar, A.; Srivastava, S. K.; Ansari, N. H. Lipid peroxidation product, 4-hydroxynonenal and its conjugate with GSH are excellent substrates of bovine lens aldose reductase. Biochem. Biophys. Res. Commun., 1995, 217, 741-746.
46. Sayre, L. M.; Zelasko, D. A.; Harris, P. L. R.; Perry, G.; Salomon, R. G.; Smith, M. A. 4-hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem., 1997, 68, 2092-2097.
47. Horvath, J. J.; Witmer, C. M.; Witz, G. Nephrotoxicity of the 1-1 acrolein glutathione adduct in the rat. Toxicol. Appl. Pharmacol., 1992, 117, 200-207.
48. Ghilarducci, D. P.; Tjeerdema, R. S. Fate and effects of acrolein. Rev. Environ. Contam. Toxicol., 1995, 144, 95-146.
49. Alston, T. A.; Seitz, S. P.; Bright, H. J. Conversion of 3-nitro-1-propanol (miserotoxin aglycone) to cytotoxic acrolein by alcohol dehydrogenase. Biochem. Pharmacol., 1981, 30, 2719-20.
50. Segall, H. J.; Wilson, D. W.; Dallas, J. L.; Haddon, W. F. Trans-4-Hydroxy-2-Hexenal - a reactive metabolite from the macrocyclic pyrrolizidine alkaloid senecionine. Science, 1985, 229, 472-475.
51. Srivastava, S. K.; Ramana, K. V.; Bhatnagar, A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr. Rev., 2005, 26, 380-392.
52. Kumar, P. A.; Reddy, G. B. Focus on molecules: Aldose reductase. Exp. Eye Res., 2007, 85, 739-40.
53. Rittner, H. L.; Hafner, V.; Klimiuk, P. A.; Szweda, L. I.; Goronzy, J. J.; Weyand, C. M. Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis. J. Clin. Invest., 1999, 103, 1007-1013.
54. Shinmura, K.; Bolli, R.; Liu, S. Q.; Tang, X. L.; Kodani, E.; Xuan, Y. T.; Srivastava, S.; Bhatnagar, A. Aldose reductase is an obligatory mediator of the late phase of ischemic preconditioning. Circ. Res., 2002, 91, 240-246.
55. Ruef, J.; Liu, S. Q.; Bode, C.; Tocchi, M.; Srivastava, S.; Runge, M. S.; Bhatnagar, A. Involvement of aldose reductase in vascular smooth muscle cell growth and lesion formation after arterial injury. Arterioscler Thromb. Vasc. Biol., 2000, 20, 1745-1752.
56. Ramana, K. V.; Chandra, D.; Srivastava, S.; Bhatnagar, A.; Aggarwal, B. B.; Srivastava, S. K. Aldose reductase mediates mitogenic signaling in vascular smooth muscle cells. J. Biol. Chem., 2002, 277, 32063-32070.
57. Yan S. F.; Ramasamy, R.; Naka, Y.; Schmidt, A. M. Glycation, inflammation, and RAGE - A scaffold for the macrovascular complications of diabetes and beyond. Circ. Res., 2003, 93, 1159-1169.
58. Beck, F. X.; Schmolke, M.; Guder, W. G.; Dorge, A.; Thurau, K. Osmolytes in renal medulla during rapid changes in papillary tonicity. Am. J. Phys., 1992, 262, F849-F856.
59. Yancey, P. H.; Clark, M. E.; Hand, S. C.; Bowlus, R. D.; Somero, G. N. Living with water-stress - evolution of osmolyte systems. Science, 1982, 217, 1214-1222.
60. +-myo-Inositol cotransporter in MDCK cells. Am. J. Phys., 1993, 264, F20-F23.
61. --dependent betaine transporter in madin-darby canine kidney-cells by increasing transcription of the transporter gene. J. Clin. Invest., 1993, 91, 1604-1607.
62. Smardo, F. L., Jr.; Burg, M. B.; Garcia-Perez, A. Kidney aldose reductase gene transcription is osmotically regulated. Am. J. Physiol., 1992, 262, C776-782.
63. Miyakawa, H.; Woo, S. K.; Dahl, S. C.; Handler, J. S.; Kwon, H. M. Tonicity-responsive enhancer binding protein, a rel-like protein that stimulates transcription in response to hypertonicity. Proc. Natl. Acad. Sci. U. S. A., 1999, 96, 2538-2542.
64. Chiquet, M.; Reneda, A. S.; Huber, F.; Fluck, M. How do fibroblasts translate mechanical signals into changes in extracellular matrix production? Matrix Biol., 2003, 22, 73-80.
65. Han, J.; Lee, J. D.; Bibbs, L.; Ulevitch, R. J. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science, 1994, 265, 808-811.
66. Matsuda, S.; Kawasaki, H.; Moriguchi, T.; Gotoh, Y.; Nishida, E. Activation of protein-kinase cascades by osmotic shock. J. Biol. Chem., 1995, 270, 12781-12786.
67. Moriguchi, T.; Kawasaki, H.; Matsuda, S.; Gotoh, Y.; Nishida, E. Evidence for multiple activators for stress-activated protein-kinases C-Jun amino-terminal kinases - existence of novel activators. J. Biol. Chem., 1995, 270, 12969-12972.
68. Banes, A. J.; Tsuzaki, M.; Yamamoto, J.; Fischer, T.; Brigman, B.; Brown, T.; Miller, L.. Mechanoreception at the cellular level: The detection, interpretation, and diversity of responses to mechanical signals. Biochem. Cell Biol., 1995, 73, 349-365.
69. Jalali, S.; Li, Y. S.; Sotoudeh, M.; Yuan, S.; Li, S.; Chien, S.; Shyy, J. Y. J. Shear stress activates p60src-Ras-MAPK signaling pathways in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol., 1998, 18, 227-234.
70. Pozzi, A.; Zent, R. Integrins: Sensors of extracellular matrix and modulators of cell function. Nephron. Exp. Nephrol., 2003, 94, E77-E84.
71. Guan, J.L. Focal adhesion kinase in integrin signaling. Matrix Biol., 1997, 16, 195-200.
72. Voigt, S.; Gossrau, R.; Baum, O.; Loster, K.; Hofmann, W.; Reutter, W. Distribution and quantification of alpha(1)-integrin subunit in rat organs. Histochem. J., 1995, 27, 123-132.
73. Moeckel, G.W.; Zhang, L.; Chen, X.; Rossini, M.; Zent, R.; Pozzi, A. Role of integrin alpha(1)beta(1) in the regulation of renal medullary osmolyte concentration. Am. J. Physiol. Renal Physiol., 2006, 290, F223-F231.
74. Burg, M. B. Coordinate regulation of organic osmolytes in renal cells. Kidney-Int., 1996, 49, 1684-1685.
75. Saez, F.; Frenete, G.; Sullivan R. Epididymosomes and prostasomes: Their roles in posttesticular maturation of the sperm cells. J. Androl., 2003, 24, 149-154.
76. Frenette, G.; Lessard C.; Sullivan, R. Selected proteins of "prostasome-like particles" from epididymal cauda fluid are transferred to epididymal caput spermatozoa in bull. Biol. Reprod., 2002, 67, 308-313.
77. Frenette, G.; Lessard C.; Madore, E.; Fortier, M.A.; Sullivan, R. Aldose reductase and macrophage migration inhibitory factor are associated with epididymosomes and spermatozoa in the bovine epididymis. Biol. Reprod., 2003, 69, 1586-1592.
78. Frenette, G.; Lessard C.; Sullivan, R. Polyol pathway along the bovine epididymis. Mol. Reprod. Dev., 2004, 69, 448-456.
79. Frenete, G.; Michel, T.; Sullivan R. Polyol pathway in human epididymis and semen. J. Androl., 2006, 27, 233-239.
80. Ronquist, G.; Nilsson, B.O. The Janus-faced nature of prostasomes: Their pluripotency favours the normal reproductive process and malignant prostate growth. Prostate Cancer Prostatic Dis., 2004, 7, 21-31.
81. Légaré, C.; Sullivan R. Expression and localization of c-ros oncogene along the human excurrent duct. Mol. Hum. Reprod., 2004, 10, 697-703.
82. Zimmet, P.; Alberti, K.G.M.M.; Shaw, J. Global and societal implications of the diabetes epidemic. Nature, 2001, 414, 782-787.
83. Tripathi, B.K. & Srivastava, A.K. Diabetes mellitus: Complications and therapeutics. Med. Sci. Monit., 2006, 12, RA130-RA147.
84. Fujisawa, T.; Ikegami, H.; Kawaguchi, Y.; Nojima, K.; Kawabata, Y.; Ono, M.; Nishino, M.; Noso, S.; Taniguchi, H.; Horiki, M.; Itoi-Babaya, M.; Babaya, N.; Inoue, K.; Ogihata, T. Common genetic basis between type 1 and type 2 diabetes mellitus indicated by interview-based assessment of family history. Diabetes Res. Clin. Pract., 2004, 66S, S91-S95.
85. Constantino, L.; Rastelli, G.; Vianello, P.; Cignarella, G.; Barlocco, D. Diabetes complications and their potential prevention: Aldose reductase inhibition and other approaches. Med. Res. Rev., 1999, 19, 3-23.
86. Rolo, A.P.; Palmeira, C.M. Diabetes and mitochondrial function: Role of hyperglycaemia and oxidative stress. Toxicol. Appl. Pharmacol., 2006, 212, 167-168.
87. Nishikawa, T.; Kukidome, D.; Sonoda K.; Fujisawa, K.; Matsuhisa, T.; Motoshima, H.; Araki, E. Impact of mitochondrial ROS production on diabetic vascular complications Diabetes Res. Clin. Pract., 2007, 77S, S41-S45.
88. De Vriese, A.S.; Verbeuren, T.J.; Van de Voorde, J.; Lameire, N.H.; Vanhoutte, P.M. Endothelial dysfunction in diabetes. Br. J. Pharmacol., 2000, 130, 963-974.
89. Nishikawa, TA; Edelstein, D.; Brownlee, M.: The missing link: a single unifying mechanism for diabetic complications. Kidney Int., 2000, 58 (S77), S26-S30.
90. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature, 2001, 414, 813-820.
91. Obrosova, I.G.; Minchenko, A.G.; Vasupuram, R.; White, L.; Abatan, O.I.; Kumagai, A.K.; Frank, R.N.; Stevens, M.J. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes, 2003, 52, 864-871.
92. Mylari, B.L.; Armento, S.J.; Beebe, D.A.; Conn, E.L.; Coutcher, J.B.; Dina, M.S.; O'Gorman, M.T.; Linhares, M.C.; Martin, W.H.; Oates, P.J.; Tess, D.A.; Withbroe, G.J.; Zembrowski, W.J. A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5- chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners. J. Med. Chem., 2005, 48, 6326-6339.
93. Srivastava, S.K.; Ramana, K.V.; Bhatnagar, A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr. Rev., 2005, 26, 380-392.
94. Hotta, N.: New approaches for treatment in diabetes - aldose reductase inhibitors. Biomed. Pharmacother., 1995, 49, 232-243.
95. Yabe-Nishimura, C. Aldose reductase in glucose toxicity: A potential target for the prevention of diabetes complications. Pharmacol. Rev., 1998, 50, 21-33.
96. Vincent, A.M.; Russell, J.W.; Low, P.; Feldman, E.L. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr. Rev., 2004, 25, 612-628.
97. Roscic, M.; Horvat, S. Transformations of bioactive peptides in the presence of sugars - Characterization and stability studies of the adducts generated via the Maillard reaction. Biorg. Med. Chem., 2006, 14, 4933-4943.
98. Khalifah, R.G.; Baynes, J.W.; Hudson, E.G. Amadorins: Novel post-Amadori inhibitors of advanced glycation reactions. Biochem. Biophys. Res. Commun., 1999, 257, 251-258.
99. Vinson, J.A.; Howard III, T.B. Inhibition of protein glycation and advanced glycation end products by ascorbic acid and other vitamins and nutrients. J. Nutr. Biochem., 1996, 7, 659-663.
100. Ramana, K.V.; Friedrich, B.; Tammali, R.; West, M.B.; Bhatnagar, A.; Srivastava, S.K. Requirements of aldose reductase for the hyperglycaemic activation of protein kinase C and formation of diacylglycerol in vascular smooth muscle cells. Diabetes, 2006, 54, 818-829.
101. Ramana, K.V.; Friedrich, B.; Srivastava, S.; Bhatnagar, A.; Srivastava, S.K. Activation of nuclear factor-κB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase. Diabetes, 2004, 53, 2910-2920.
102. Harada, C.; Okumura, A.; Namekata, K.; Nakamura, K.; Mitamura, Y.; Ohguro, H.; Harada, T. Role of monocyte chemotactic protein-1 and nuclear factor kappa B in the pathogenesis of proliferative diabetic retinopathy. Diabetes Res. Clin. Pract., 2006, 74, 249-256.
103. Obrosova, I.G.; Pacher, I.; Szabó, C.; Zsengeller, Z.; Hirooka, H.; Stevens, M.J.; Yorek, M.A. Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications. Diabetes, 2006, 54, 234-242.
104. Oyama, T.; Miyashita, Y.; Watanabe, H.; Shirai, K. The role of polyol pathway in glucose-induced endothelial cell damages. Diabetes Res. Clin. Pract., 2006, 73, 227-234.
105. Rösen, P.; Nawroth, P.P.; King, G.; Möller, W.; Trischler, H.J.; Packer, L. The role of oxidative stress on the onset and progression of diabetes and its complications: A summary of a congress series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab. Res. Rev., 2001, 17, 189-212.
106. Gleissner, C.A.; Galkina, E.; Nadler, J.L.; Ley, K.: Mechanisms by which diabetes increases cardiovascular disease. Drug Discov. Today Dis. Mech., 2007, 4, 131-140.
107. Dunlop, M. Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int., 2000, 58, S3-S12.
108. Suzuki, D.; Miyata, T.; Saotome, N.; Horie, K.; Inagi, R.; Yasuda, Y.; Uchida, K.; Izuhara, Y.; Yagame, M.; Sakai, H.; Korokawa, K. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am. Soc. Nephrol., 1999, 10, 822-832.
109. Horie, K.; Miyata, T.; Maeda, K.; Miyata, S.; Sugiyama, S.; Sakai, H.; Van Ypersele de Strihou, C.; Monnier, V.M.; Witztum, J.L.; Kurokawa, K. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. J. Clin. Invest., 1997, 100, 2995-3004.
110. Ramasamy, R.; Liu, P.J.; Oates, S.S. Attenuation of ischemia induced increases in sodium and calcium by the aldose reductase inhibitor Zopolrestat. Cardiovasc. Res, 1999, 42, 130-139.
111. Kaneko, M.; Ramasamy, M. Aldose reductase: A key player in myocardial ischemic injury. Exerc. Sport Sci. Rev., 2004, 32, 19-23.
112. Hwang, Y.C.; Kaneko, M.; Bakr, S.; Liao, H.; Lu,Y.; Lewis, E.R.; Yan,S.; Ii, S.; Itakura, M.; Rui, L.; Skopicki, H.; Homma, S.; Schmidt, A.M.; Oates, P.J.; Szabolcs, M.; Ramasamy, R. Central role for aldose reductase pathway in myocardial ischemic injury. FASEB J., 2004, 18, 1192-1199.
113. Iwaka, K.; Matsuno, K.; Nishinaka, T.; Persson, C.; Yabe-Nishimura, C. Aldose reductase inhibitors improve myocardial reperfusion injury in mice by a dual mechanism. J. Pharmacol. Sci., 2006, 102, 37-46.
114. Ross, R. The pathogenesis of atherosclerosis - A perspective for the 1990s. Nature, 1993, 362, 801-809.
115. Ramana, K.V.; Willis, M.S.; White, M.D.; Horton, J.W.; DiMaio, J.M.; Srivastava, D.; Bhatnagar, A.; Srivastava, S.K. Endotoxin-induced cardiomyopathy and systemic inflammation in mice is prevented by aldose reductase inhibition. Circulation, 2006, 114, 1838-1846.
116. Ramana, K.V.; Fadl, A.A.; Tammali, R.; Reddy, A.B.M.; Chopra, A.K.; Srivastava, S.K. Aldose reductase mediates the lipopolysaccharide-induced release of inflammatory mediators in RAW264.7 murine macrophages. J. Biol. Chem., 2006, 281, 33019-33029.
117. Ramana, K.V.; Reddy, A.B.M.; Tammali, R.; Srivastava, S.K.: Aldose reductase mediates endotoxin-induced production of nitric oxide and cytotoxicity in murine macrophages. Free Rad. Biol. Med., 2007, 42, 1290-1302.
118. Landry, D.W.; Oliver, J.A. Mechanisms of disease: The pathogenesis of vasodilatory shock. N. Engl. J. Med., 2001, 345, 588-595.
119. Yadav, U.C.S.; Srivastava, S.K.; Ramana, K.V. Aldose reductase inhibition prevents endotoxin-induced uveitis in rats. Invest. Ophth. Vis. Sci., 2007, 48, 4634-4642.
120. Viinamaki, H.; Niskanen, L.; Uusitupa, M. Mental well-being in people with non-insulin-dependent diabetes. Acta. Psychiatr. Scand., 1995, 92, 392-397.
121. Regenold, W.T.; Phatak, P.; Kling, M.A.; Hauser, P. Post-mortem evidence from human brain tissue of disturbed glucose metabolism in mood and psychotic disorders. Mol. Psych., 2004, 9, 731-733.
122. Kling, M.A.; Neuhaus, I.; Gold, P.W. Psychiatric-hormonal interrelationships. Principles and Practice of Endocrinology and Metabolism, Lippincott Company: Philadelphia, 1995; pp 1696-1702.
123. Goldstein, L.E.; Sporn, J.; Brown, S.; Kim, H.; Finkelstein, J.; Gaffey, G.K.; Sachs, G.; Stern, T.A. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics, 1999, 40, 438-843.
124. Cohen, M.M. TGFβ/Smad Signaling System and its Pathologic Correlates. Am. J. Med. Gene, 2003, 116A, 1-10.
125. Jiang, T.; Che, C.; Lin, Y.; Li, L.; Zhang, N. Aldose reductase regulates TGF-β1-induced production of fibronectin and type IV collagen in cultured rat mesangial cells. Nephrology, 2006, 11, 105-112.
126. Hasuike, Y.; Moriguchi, R.; Hata, R.; Miyagawa, K.; Kuragano, T.; Aizawa, M.; Yamamoto, S.; Yanase, K.; Izumi, M.; Tanimoto, T.; Nakanishi, T. Role of aldose reductase in the peritoneal changes of patients undergoing peritoneal dialysis. Am. J. Nephrol., 2007, 27, 622-629.
127. Liu, G.; Hale, G.E.; Hughes, C. Galactose metabolism and ovarian toxicity. Reprod. Toxicol., 2000, 14, 377-384.
128. Berry, G.T. The role of polyols in the pathophysiology of hypergalactosemia. Eur. J. Pediatr., 1995, 154, S53-64.
129. Cao, D.; Tat Fan, S.; Chung, S. Identification and characterization of a novel human aldose reductase-like gene. J. Biol. Chem., 1998, 273(19), 11429-11435.
130. Ax, W.; Soldan, M.; Koch, L.; Maser, E. Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem. Pharmacol., 2000, 59, 293-300.
131. Plebuch, M.; Soldana, M.; Hungerera, C.; Kocha, L.; Maser, E. Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes. Cancer Lett., 2007, 255, 49-56.
132. Lewis, T.S.; Shapiro, P.S.; Ahn, N.G. Signal transduction through MAP kinase cascades. Adv. Cancer Res., 1998, 74, 49-139.
133. Wang, X.; Martindale, J.L.; Holbrook, N.J. Requirement for ERK activation in Cisplatin-induced apoptosis. J. Biol. Chem., 2000, 275, 39435-39443.
134. Lee, E.K.; Tegenold, W.T.; Shapiro, P. Inhibition of aldose reductase enhances HeLa cell sensitivity to chemotherapeutic drugs and involves activation of extracellular signal-regulated kinases. Anti-Cancer Drug, 2002, 13, 859-868.
135. Ramana, K.V.; Bhatnagar, A.; Srivastava, S.K. Inhibition of aldose reductase attenuates TNF-??-induced expression of adhesion molecules in endothelial cells. FASEB J., 2004, 18, 1209-1218.
136. Kang, E.S.; Kima, H.J.; Paekb, K.S.;.Janga, H.-S.; Changa, K.C.; Lee J.H.; Nishinaka, T.; Yabe-Nishimura, C.; Seo, H.G. Phorbol ester up-regulates aldose reductase expression in A549 cells: A potential role for aldose reductase in cell cycle modulation. CMLS, Cell. Mol. Life Sci., 2005, 62, 1146-1155.
137. Gupta, R.A.; Dubois, R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer, 2001, 1, 11-21.
138. Tammali, R.; Ramana, K.V.; Singhal, S.S.; Awasthi, S.; Srivastava, K. Aldose reductase regulates growth factor-induced cyclooxygenase-2 expression and prostaglandin E2 production in human colon cancer cells. Cancer Res., 2006, 66, 9705-9713.
139. Tammali, R.; Ramana, K.V.; Srivastava, K. Aldose reductase regulates TNF-α-induced PGE2 production in human colon cancer cells. Cancer Lett., 2007, 252, 299-306.
140. Kopf, D.; Goretzki, P.; Lehnert, H. Clinical management of malignant adrenal tumors. J. Cancer Res. Clin. Oncol., 2001, 127, 143-155.
141. Lefrançois-Martinez, A-M.; Bertherat, J.; Val, P.; Tournaire, C.; Gallo-Payet, N.; Hyndman, D.; Sveyssiere, G.; Bertagna, H.; Jean, C.; Martinez, A. Decreased expression of cyclic adenosine monophospate-regulated aldose reductase (AKR1B1) is associated with malignancy in human sporadic adrenocortical tumors. J. Clin. Endocr. Metab., 2004, 89, 3010-3019.
142. Rosenberg, D.; Groussin, L.; Jullian, E.; Perlemoine, K.; Medjane, S.; Louvel, A.; Bertagna, X.; Bertherat, J. Transcription factor 3′,5′-cyclic adenosine 5′-monophosphate-responsive element-binding protein (CREB) is decreased during human adrenal cortex tumorigenesis and fetal development. J. Clin. Endocrinol. Metab., 2003, 88, 3958-3965.
143. Bertherat, J.; Groussin, L.; Sandrini, F.; Matyakhina, L.; Bei, T.; Stergiopoulos, S.; Papageorgiou, T.; Bourdeau, I.; Kirschner, L.S.; Vincent-Dejean, C.; Perlemoine, K.; Gicquel, C.; Bertagna, X.; Stratakis, C.A. Molecular and and functional analysis of PRKAR1A and its Locus (17q22-24) in sporadic adenocortical tumors. Cancer Res., 2003, 63, 5308-5319.
144. Fukumoto, S.; Yamauchi, N.; Moriguchi, H.; Ito, H.; Yamamoto, S.; Iwanari, A.; Shibahara, J.; Taniguchi, H.; Ishikawa, S.; Ito, H.; Hamamoto, S.; Iwanari, H.; Hironaka, M. Overexpression of the Aldo-Keto Reductase family protein AKR1B10 is highly correlated with smokers non-small cell lung carcinomas. Clin. Cancer Res., 2005, 11, 1776-1785.
145. Penning, T.M. AKR1B10: A new diagnostic marker of non-small cell lung carcinomas in smokers. Clin. Cancer Res., 2005, 11, 1687-1690.
146. Yan, R.; Zu, X.; Ma, J.; Liu, Z.; Adeyanju, M, Cao, D. Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention. Int. J. Cancer, 2007, 121, 2301-2306.
147. Ma, J.; Yan, R.; Zu, X.; Cheng, J-M.; Rao, K.; Liao, D-F.; Cao, D. Aldo-Keto Reductase family 1 B10 affects fatty acids synthesis by regulating the stability of acetyl-CoA carboxylase - a in breast cancer cells. J. Biol. Chem., 2008, 283, 3418-3423.
148. Kuhajda, F.P. Fatty-acid synthase and human cancer: New perspectives on its role in tumor biology. Nutrition, 2000, 16, 202-208
149. Malamas, S. M.; Millen, J. Quinazolineacetic acids and related analogs as aldose reductase inhibitors. J. Med. Chem., 1991, 34, 1492-1503.
150. Bruno, G.; Constantino, L.; Curinga, C.; Maccari, R.; Monforte, F.; Nicolo, F.; Ottana, R.; Vigorita, G. M. Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones. Bioorg. Med. Chem., 2002, 10, 1077-1084.
151. Da Settimo, F.; Primofiore, C.; Da Settimo, A.; La Motta, C.; Taliani, S.; Simorini, F.; Novellino, E.; Greco, G.; Lavecchia, A.; Boldrin, E. [1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: A new class of selective aldose reductase inhibitors. J. Med. Chem., 2001, 44, 4359-4369.
152. Nicolaou, I.; Demopoulos, V. J. Substituted pyrrol-1-yl acetic acids which combine aldose reductase enzyme inhibitory activity and ability to prevent the non enzymatic irreversible modification of proteins from monosaccharides. J. Med. Chem. 2003, 46, 417-426.
153. Zaher, N.; Nicolaou, I.; Demopoulos, V. J. Pyrrolylbenzothiazole derivatives as aldose reductase inhibitors. J. Enzyme Inhib. Med. Chem., 2002, 17, 131-135.
154. Pau, A.; Asproni, B.; Boatto, G.; Grella, G.E.; De Caprariis, P.; Constantino, L.; Pinna, G.A. Synthesis and aldose reductase inhibitory activities of novel thienocinnolinone derivatives. Eur. J. Pharm. Sci., 2004, 21, 545-552.
155. Rakowitz, D.; Gmeiner, A.; Schröder, N.; Matuszczak, B. Synthesis of novel phenylacetic acid derivatives with halogenated benzyl subunit and evaluation as aldose reductase inhibitors. Eur. J. Pharm. Sci., 2006, 27, 188-193.
156. Rakowitz D.; Piccolruaz, G.; Pirker, C.; Matuszczak, B. Novel Aldose Reductase Inhibitors Derived from 6- (Diphenylmethylene) amino]oxy] hexanoic acid. Arch. Pharm. Chem. Life Sci., 2007, 340, 202-208.
157. Ashizawa, N.; Aotsuka, T. Benzothiazole aldose reductase inhibitors. Drugs Fut., 1998, 23, 521-526.
158. Tsantili-Kakoulidou, A.; Nicolaou, I.; Vrakas, D.; Demopoulos, V. J. Modelling of aldose reductase inhibitory activity of pyrrol-1-ylacetic acids derivatives by means of multivariate statistics. Med. Chem., 2005, 1, 321-326.
159. Negoro, T.; Murata, M.; Ueda, S.; Fujitani, B.; Ono, Y.; Kuromiya, A.; Komiya, M.; Suzuki, K.; Matsumoto, J. Novel, highly potent aldose reductase inhibitors: (R)-(??)-2-(4-Bromo-2-fluorobenzyl)- 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine- 4-spiro-3′-pyrrolidine-1,2′,3,5′-tetrone (AS-3201) and its congeners. J. Med. Chem., 1998, 41, 4118-4129.
160. Inoue, J.; Cui, Y.; Sakai, O.; Nakamura, Y.; Kogiso, H.; Kador, P. Synthesis and aldose reductase inhibitory activities of novel N-nitromethylsulfonanilide derivatives. Bioorg. Med. Chem., 2000, 8, 2167-2173.
161. Nicolaou, I.; Zika, Ch.; Demopoulos, V. J. 1-(3,5-difluoro-4- hydroxyphenyl)-1H-pyrrol-3-yl) phenylmethanone as a bioisostere of a carboxylic acid aldose reductase inhibitor. J. Med. Chem., 2004, 47, 2706-2709.
162. Alexiou, P.; Nicolaou, I.; Stefek, M.; Kristl, A.; Demopoulos, V. J. Design and synthesis of N-(3,5-difluoro-4-hydroxyphenyl)benzenesulfonamides as aldose reductase inhibitors. Bioorg. Med. Chem., 2008, 16, 3926-3932.
163. Stefek, M.; Snirc, V.; Djoubissie, P-O.; Majekova, M.; Demopoulos, V.J.; Rackova, L.; Bezakova, Z.; Karasu, C.; Carbone, V.; El-Kabbani, O. Carboxymethylated pyridoindole antioxidants as aldose reductase inhibitors: Synthesis, activity, partitioning, and molecular modeling. Bioorg. Med. Chem., 2008, 16, 4908-4920.
164. Ko, K.; Won, Y. Quantitative structure and aldose reductase inhibitory activity relationship of 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine- 4-spiro-3′-pyrrolidine-1,2′,3,5′-tetrone derivatives. Bioorg. Med. Chem., 2005, 13, 1445-1452.
165. Maccari, R.; Ottana, R.; Curinga, C.; Vigorita, M.G.; Rakowitz, D.; Steindl, T.; Langer, T. Structure-activity relationships and molecular modelling of 5-arylidene-2,4-thiazolidinediones active as aldose reductase inhibitors. Bioorg. Med. Chem., 2005, 13, 2809-2823.
166. Sambasivara, S.G.; Soni, K.L.; Gupta, K. A.; Hanumantharao, P.; Kaskhedikar, S.G. Quantitative structure-activity analysis of 5-arylidene-2,4-thiazolidinediones as aldose reductase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 512-521.
167. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug. Deliv. Rev., 1997, 23, 3-25.
168. Sturn, K.; Levstik, L., Demopoulos, V. J.; Kristl, A. Permeability characteristics of novel aldose reductase inhibitors using rat jejunum in vitro. Eur. J. Pharm. Sci., 2006, 28, 128-133.
169. Polli, J.E.; Yu, L.X.; Cook, J.A.; Amidon, G.L.; Borchardt, R.T.; Burnside, B.A.; Burton, P.S.; Chen, M.L.; Conner, D.P.; Faustino, P.J.; Hawi, A.A.; Hussain, A.S.; Joshi, H.N.; Kwei, G.; Lee, V.H.; Lesko, L.J.; Lipper, L.A.; Lopper, A.E.; Nerurkar, S.G.; Polli, J.W.; Sanvorde, R.; Taneja, R.S.; Uppoor, C.; Vattikonda, S.; Wilding, I.; Zhang, G. Summary workshop report: Biopharmaceutics classification system - implementation challenges and extension opportunities. J. Pharm. Sci., 2004, 93, 1375-1381.
170. Pagliara, A.; Carrupt, P-A.; Caron, G.; Gaillard, P.; Testa, B. Lipophilicity profiles of ampholytes. Chem. Rev., 1997, 97, 3385-3400.
171. Lee, Y. S.; Paek, K. S; Kang, E. S.; Jang, H-S.; Kim, H.; Kang, Y. J.; Kim, J-H.; Lee, H. T.; Lee, J. H.; Chang, K. C.; Nishikaka, T.; Seo, H. G. Involvement of nuclear factor kappaB in up-regulation of aldose reductase gene expression by 12-O-tetradecanoylphorbol-13-acetate in HeLa cells. Int. J. Biochem. Cell. Biol., 2005, 37, 2297-2309.